Oruka Therapeutics (NASDAQ:ORKA) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Oruka Therapeutics (NASDAQ:ORKA) from a hold rating to a sell rating in a report published on Saturday.

Several other analysts have also recently issued reports on the company. BTIG Research started coverage on Oruka Therapeutics in a research note on Thursday, May 22nd. They issued a “buy” rating on the stock. Wedbush reiterated an “outperform” rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research note on Thursday, May 15th. One analyst has rated the stock with a sell rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Oruka Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $40.38.

Oruka Therapeutics Stock Down 1.0%

NASDAQ:ORKA opened at $12.43 on Friday. The stock’s fifty day moving average is $10.39 and its two-hundred day moving average is $12.96. Oruka Therapeutics has a 52 week low of $5.49 and a 52 week high of $31.13. The stock has a market capitalization of $465.39 million, a price-to-earnings ratio of -1.98 and a beta of -0.38.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.17. On average, sell-side analysts expect that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Institutional Trading of Oruka Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in Oruka Therapeutics by 4,161.2% in the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company’s stock valued at $31,231,000 after buying an additional 1,572,853 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Oruka Therapeutics during the fourth quarter worth about $343,000. Squarepoint Ops LLC purchased a new position in shares of Oruka Therapeutics during the fourth quarter worth about $236,000. Millennium Management LLC purchased a new position in shares of Oruka Therapeutics during the fourth quarter worth about $588,000. Finally, Geode Capital Management LLC grew its holdings in shares of Oruka Therapeutics by 2,348.6% during the fourth quarter. Geode Capital Management LLC now owns 342,418 shares of the company’s stock worth $6,643,000 after purchasing an additional 328,434 shares during the last quarter. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.